Merus
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.
MRUS Key Statistics
Stock Snapshot
With a market cap of 7.27B, Merus(MRUS) trades at $95.82. The stock has a price-to-earnings ratio of -17.99.
During the trading session on 2025-11-17, Merus(MRUS) shares reached a daily high of $96.17 and a low of $95.78. At a current price of $95.82, the stock is +0.0% higher than the low and still -0.4% under the high.
Trading volume for Merus(MRUS) stock has reached 1.19M, versus its average volume of 1.08M.
Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $96.28 and a low of $33.19.
Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $96.28 and a low of $33.19.
MRUS News
(RTTNews) - Monday, Merus N.V. (MRUS) has entered into a global non-exclusive collaboration and license agreement regarding Halozyme Therapeutics, Inc.'s ENHANZ...
Merus (MRUS) and Halozyme Therapeutics (HALO) announced they have entered into a global non-exclusive collaboration and license agreement. Under the collaborati...
Merus N.V. reported its third quarter 2025 earnings, showing revenue of US$12.15 million and a net loss of US$95.52 million, with the nine-month loss rising to...
Analyst ratings
88%
of 17 ratingsMore MRUS News
In recent trading, shares of Merus NV (Symbol: MRUS) have crossed above the average analyst 12-month target price of $44.30, changing hands for $46.03/share. Wh...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
New activity is brewing for Merus ( (MRUS) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shar...